Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 4

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 
  
    Net loss 
     -  
     -  
     -  
     (4,532,430) 
     (4,532,430)

    Balance, March 31, 2025 
     572,389  
    5,724  
    67,765,620  
    (64,971,613) 
    2,799,731 

    Issuance of shares of common stock, net of issuance costs (Note 6c) 
     32,574  
     326  
     574,743  
     -  
     575,069 
  
    Stock-based compensation 
     -  
     -  
     180,763  
     -  
     180,763 
  
    Net loss 
     -  
     -  
     -  
     (5,228,919) 
     (5,228,919)

    Balance, June 30, 2025 
     604,963  
    6,050  
    68,521,126  
    (70,200,532) 
    (1,673,356)
  
    Balance 
     604,963  
    $6,050  
    $68,521,126  
    $(70,200,532) 
    $(1,673,356)

    Issuance of common stock and warrants upon conversion of promissory notes, net of issuance costs (Note 7) 
     501,566  
     5,016  
     6,854,625  
     -  
     6,859,641 
  
    Exercise of pre-funded warrants 
     15,391  
     154  
     -  
     -  
     154 
  
    Issuance of shares of common stock, net of issuance costs (Note 6d) 
     520,000  
     5,200  
     2,238,591  
     -  
     2,243,791 
  
    Stock-based compensation 
     -  
     -  
     150,614  
     -  
     150,614 
  
    Net loss 
     -